Who
Chen Schor
President & CEO
Company insider
Files Form 4 as: President & CEO, Adicet Bio; Director, Karyopharm Therapeutics; Director, Brainstorm Cell Therapeutics; Former President and CEO, Madrigal Pharmaceuticals; Chief Business Officer, EPIX Pharmaceuticals.
In numbers
- Trades disclosed
- 158
- Buys
- 5
- Sells
- 19
- Bought
- $69K
- Sold
- $5.1M
- Companies
- 5
- Companies where not an officer
- 2
- First trade
- 16 Aug 2006
- Last trade
- 19 Jun 2026
- Last filed
- 23 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 19 Jun 2026filed 23 Jun 2026 | ACET Adicet Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —55,000 at $0.00 | filing |
| 19 Jun 2026filed 23 Jun 2026 | ACET Adicet Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —55,000 at $0.00 | filing |
| 21 May 2026filed 26 May 2026 | KPTI Karyopharm TherapeuticsBiotechnology | SEC FORM 4 Code A | —15,508 at $0.00 | filing |
| 21 May 2026filed 26 May 2026 | KPTI Karyopharm TherapeuticsBiotechnology | SEC FORM 4 Code A | —15,508 at $0.00 | filing |
| 25 Mar 2026filed 27 Mar 2026 | ACET Adicet Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —468,555 at $0.00 | filing |
| 25 Mar 2026filed 27 Mar 2026 | ACET Adicet Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —468,555 at $0.00 | filing |
| 24 Jan 2026filed 27 Jan 2026 | ACET Adicet BioBiotechnology | SEC FORM 4 Code F | $15K1,755 at $8.44 | filing |
| 24 Jan 2026filed 27 Jan 2026 | ACET Adicet BioBiotechnology | SEC FORM 4 Code F | $15K1,755 at $8.44 | filing |
| 28 May 2025filed 29 May 2025 | KPTI Karyopharm Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,600 at $0.00 | filing |
| 31 Jan 2025filed 4 Feb 2025 | ACET Adicet Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —763,829 at $0.00 | filing |
| 24 Jan 2025filed 28 Jan 2025 | ACET Adicet BioBiotechnology | SEC FORM 4 Code F | $26K28,101 at $0.92 | filing |
| 5 Jun 2024filed 7 Jun 2024 | ACET Adicet Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —1,770,427 at $0.00 | filing |
| 29 May 2024filed 30 May 2024 | KPTI Karyopharm Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —69,000 at $0.00 | filing |
| 24 Jan 2024filed 26 Jan 2024 | ACET Adicet Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —1,116,903 at $0.00 | filing |
| 24 Jan 2024filed 26 Jan 2024 | ACET Adicet BioBiotechnology | SEC FORM 4 Code F | $37K15,290 at $2.40 | filing |
| 24 Jan 2024filed 26 Jan 2024 | ACET Adicet BioBiotechnology | SEC FORM 4 Code A | —70,300 at $0.00 | filing |
| 2 Oct 2023filed 2 Oct 2023 | ACET Adicet BioBiotechnology | SEC FORM 4 Bought | $7,3155,500 at $1.33 | filing |
| 2 Oct 2023filed 2 Oct 2023 | ACET Adicet BioBiotechnology | SEC FORM 4 Code F | $32K23,208 at $1.37 | filing |
| 29 Sep 2023filed 2 Oct 2023 | ACET Adicet BioBiotechnology | SEC FORM 4 Sold | $7,4805,500 at $1.36 | filing |
| 28 Sep 2023filed 2 Oct 2023 | ACET Adicet BioBiotechnology | SEC FORM 4 Sold | $7,8105,500 at $1.42 | filing |
News
No headline names them, or the companies they trade most, lately.